RxDoctor Payments Data

Pietro Rondinelli

Physician Assistant · South Windsor, CTNPI 1831408632

Payments from drug & device makers

$3,093in general payments, 2019–2025

Across 109 payments — averaging $28.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$917
  • AbbVie$456
  • Ardelyx, Inc.$272
  • Aimmune Therapeutics, Inc.$254
  • Takeda Pharmaceuticals U.S.A., Inc.$216
  • Johnson & Johnson$183
  • plus $795 from 16 others

What the payments were for

  • Travel & lodging$55618%
  • Food & beverage$2,36576%
  • Education$1726%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,093 in reported general payments places this provider in the 90th percentile of 1,795 physician assistant providers in Connecticut.

See all physician assistant providers in Connecticut

Medicare billing

Part B allowed, 2024
$19,000
Medicare patients
166
Services billed
192

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide45$49,659
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates138$7,947
TrulancePlecanatide13$6,934
Dexlansoprazole DrDexlansoprazole12$3,827
Pantoprazole Sodium218$3,438
SutabSod Sulf/Pot Chloride/Mag Sulf16$2,612
Omeprazole120$2,057
Famotidine104$2,044
Budesonide EcBudesonide13$1,807
Esomeprazole Magnesium23$1,018
Dicyclomine Hcl35$822
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg45$726
Sucralfate26$649
Lansoprazole24$451
Ondansetron OdtOndansetron19$310

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$456$49,65945 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$61$6,93413 claims
Braintree Laboratories, Inc.Sutab$35$2,61216 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,795 physician assistant providers in Connecticut.

Other physician assistant in South Windsor

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →